In 2023, nearly 1 in 4 US adults were living with chronic pain, and 8.5% experienced pain severe enough to limit daily life ...

The listening room with a bespoke sound system reflecting Alessandro Michele's vision was conceived in partnership with ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...

EPS and sales below estimates but raised its 2025 revenue outlook, driven by CF drug demand and new product launches in the U ...

Cheng Xin / Getty Images Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of ...

In addition, Vertex revealed that it has temporarily paused the multiple ascending dose portion of its phase 1/2 study evaluating experimental messenger RNA (mRNA) therapy VX-522 in treating ...

Mari Villar was slammed by a car that jumped the curb, breaking her legs and collapsing a lung. Amy Paulo was in pain from a femur surgery that wasn’ t healing properly. But recoveries are routinely ...